Back to Search
Start Over
Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4751-4751, 1p
- Publication Year :
- 2023
-
Abstract
- Background: The previous standard Canadian approach to autologous stem cell transplantation (ASCT) included CyBorD induction and single-agent lenalidomide maintenance until progression (Cote J, et al. ASH 2022: abstract 117). In an effort to improve outcomes, the current Canadian Myeloma Research Group (CMRG)–008 trial aimed to assess the efficacy and tolerance of a regimen of isatuximab-CyBorD (Isa-CyBorD) induction, stem cell mobilization/collection, high-dose melphalan with ASCT, followed by continuous maintenance with isatuximab and lenalidomide in newly diagnosed multiple myeloma (NDMM) patients eligible for transplant. We now report the first planned analysis of Isa-CyBorD induction and stem cell mobilization and collection.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64705742
- Full Text :
- https://doi.org/10.1182/blood-2023-190168